n-methyl-3,4-methylenedioxyamphetamine has been researched along with Depressive Disorder, Major in 10 studies
N-Methyl-3,4-methylenedioxyamphetamine: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
3,4-methylenedioxymethamphetamine : A member of the class of benzodioxoles that is 1,3-benzodioxole substituted by a 2-(methylamino)propyl group at position 5.
Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Some evidence suggests that Major Depressive Disorder (MDD) is the most common psychiatric condition that arises following trauma." | 2.72 | Psilocybin and MDMA for the treatment of trauma-related psychopathology. ( Bird, CIV; Modlin, NL; Rucker, JJH, 2021) |
| "Multiple illicit substance users were more likely to use methamphetamine (p = 0." | 1.72 | Survey of substance use among adolescent drug offenders referred from juvenile courts in Taiwan: Clinical epidemiology of single versus multiple illicit substance use. ( Chen, LY; Chen, MH; Chen, YH; Wei, HT, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 6 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jones, GM | 2 |
| Nock, MK | 1 |
| Chen, YH | 1 |
| Chen, MH | 1 |
| Wei, HT | 1 |
| Chen, LY | 1 |
| Yang, KH | 1 |
| Han, BH | 1 |
| Palamar, JJ | 1 |
| Schmid, Y | 1 |
| Gasser, P | 1 |
| Oehen, P | 1 |
| Liechti, ME | 1 |
| Bird, CIV | 1 |
| Modlin, NL | 1 |
| Rucker, JJH | 1 |
| Riedel, WJ | 1 |
| Freudenmann, RW | 1 |
| Schönfeldt-Lecuona, C | 1 |
| Spitzer, M | 1 |
| Hermle, L | 1 |
| Grön, G | 1 |
| Durdle, H | 1 |
| Lundahl, LH | 1 |
| Johanson, CE | 1 |
| Tancer, M | 1 |
| Marchesi, C | 1 |
| Tonna, M | 1 |
| Maggini, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Examining the Safety and Clinical Efficacy of Psilocybin Therapy for Veterans With PTSD: An Open-Label Proof-of-Concept Trial[NCT05554094] | Phase 2 | 15 participants (Anticipated) | Interventional | 2023-01-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for n-methyl-3,4-methylenedioxyamphetamine and Depressive Disorder, Major
| Article | Year |
|---|---|
Psilocybin and MDMA for the treatment of trauma-related psychopathology.
Topics: Depressive Disorder, Major; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Stress Disor | 2021 |
9 other studies available for n-methyl-3,4-methylenedioxyamphetamine and Depressive Disorder, Major
| Article | Year |
|---|---|
Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes.
Topics: Adolescent; Adult; Aged; Depressive Disorder, Major; Female; Hallucinogens; Health Surveys; Humans; | 2022 |
Survey of substance use among adolescent drug offenders referred from juvenile courts in Taiwan: Clinical epidemiology of single versus multiple illicit substance use.
Topics: Adolescent; Criminals; Depressive Disorder, Major; Humans; Illicit Drugs; Ketamine; Methamphetamine; | 2022 |
Past-year hallucinogen use in relation to psychological distress, depression, and suicidality among US adults.
Topics: Adult; Depression; Depressive Disorder, Major; Hallucinogens; Humans; Lysergic Acid Diethylamide; N- | 2022 |
Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and psilocybin) and major depressive episodes.
Topics: Adult; Depressive Disorder, Major; Ethnicity; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamph | 2023 |
Acute subjective effects in LSD- and MDMA-assisted psychotherapy.
Topics: Adult; Combined Modality Therapy; Compassionate Use Trials; Consciousness Disorders; Depressive Diso | 2021 |
Cognitive changes after acute tryptophan depletion: what can they tell us?
Topics: Alzheimer Disease; Cognition Disorders; Depressive Disorder, Major; Human Experimentation; Humans; N | 2004 |
Electroconvulsive therapy in the treatment of depression in a former ecstasy user.
Topics: Adrenergic Uptake Inhibitors; Adult; Depressive Disorder, Major; Drug Resistance; Electroconvulsive | 2006 |
Major depression: the relative contribution of gender, MDMA, and cannabis use.
Topics: Adult; Comorbidity; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorder | 2008 |
Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse.
Topics: Adolescent; Amphetamine-Related Disorders; Antidepressive Agents, Tricyclic; Antipsychotic Agents; B | 2009 |